In addition, HMGB1 promotes the release of IL-6 and IL-8 by activating MAPK- and MyD88-dependent NF-κB pathways, resulting in promoted tumor proliferation, angiogenesis, EMT, invasion and metastasis (75). Here, MYD88 is linked to neoplasm.